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Long-Term (25-Year) Survival After Renal Homotransplantation-The 
World Experience 
T.E. Starzl, G.P.J. Schroter, N.J. Hartmann, N. Barfield, P. Taylor, and T.L. Mangan 
AT the beginning of 1962, renal transplantation, except 
with an identical twin donor, was not a promising 
means of treatment. Total body irradiation 1.2 6-mercapto-
purineIP~ its analogue, azathioprine? and steroids8 had 
been shown in dogs and/or rodents to have immunosup-
pressive qualities. but prolonged survival of skin or kidney 
grafts in experimental animals was a relatively uncommon 
achievement. Similarly, the first clinical trials with these 
agents, alone or in combination, had been almost univer-
sally unsuccessful. Y- J4 
METHODS 
It was known from our own unpublished canine experiments that 
steroids and azathioprine had synergistic immunosuppressive 
effects. As it turned out, this kind of multimodality therapy 
allowed the prevention or reversal of rejection of renal homografts 
in most clinical cases. 15 Consequently, an extensive and encour-
aging clinical experience (Table 1) with 64 patients was quickly 
acquired at the University of Colorado. 16 Forty-six patients were 
given kidneys from blood relatives other than identical twins. The 
other 18 received kidneys from nonrelated volunteer donors. 
Fifteen of the recipients survived for 25 years and 14 are still living 
after 25Y, to 27 years. These long-surviving recipients are the 
principal basis of this report. 
In addition, with the help of colleagues at 6 other centers which 
were active in these early years, 9 more patients have been found 
who have survived to date after treatment with renal homotrans-
plantation during this same time frame. 
RESULTS 
Forty-Six Recipients of Living Related Kidneys 
Fourteen (30%) of 46 recipients of living related kidneys in 
the original University of Colorado series are still alive 
after 25Yz to 27 years (Table 2). The 25-year survival rate in 
this group was 15/46 (33%), but one of the patients died 
after 25.3 years with function of his original maternal graft 
(Cr 2.0 mg %). Ten of the 14 survivors have their original 
grafts (Table 2), and all have serum creatinines less than 2 
mg%. 
Recipients of Sibling Kidneys. Only 3 (13%) of the 23 
recipients of sibling kidneys are alive (Table 1). They have 
good function of their original transplants, the first two of 
which are the longest surviving homografts in the world. 
These 3 patients are males. Their grafts were placed on 31 
January 1963 (from a sister), 9 February 1963 (brother), 
and 15 January 1964 (sister) (Table 2). The first of these 
recipients was A blood type and received a B kidney, a 
blood group incompatibility that is generally avoided to-
day. The last 2 of the 3 surviving recipients stopped all 
therapy 25 and 23 years ago because of mental illness and 
religious convictions respectively. Renal function has been 
perfect throughout. Why treatment could be stopped per-
manently is not known. Noncompliance of this kind often 
has been described in the literature as an important cause 
of graft loss. 
Recipients of Parental Kidneys. Nine (45%) of the 20 
recipients of parental kidneys are alive (Table 1) and 5 still 
have adequate function of their original grafts. Two more 
have undergone successful retransplant at ion with related 
donors and two are on dialysis (Table 2). 
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Table 1. Living Donor Renal Transplants From November 1962 to March 1964 
Alive in Years 
Function Now Off Dialysis 
Number 5 10 20 25 Now of Original Graft Now 
Non-Twin Relatives 46 28 24 17 15 14 10 12 
Sibling 23 11 8 4 3 3 3 3 
Parental 20 14 13 11 10 9 5 7 
Other- 3 3 3 2 2 2 2 2 
Non Related 18 2 2 0 0 0 0 
• Aunt, Uncle. or Cousin. 
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Table 2. Fourteen Surviving Patients From 1962 to 1964 Table 4. Outcome of Pediatric Recipients Treated From Novem-
(March) Series ber 24,1962 to March 23, 1964, Follow-up to September 1,1989 
Renal Function LD Tx Date Donor Age/Sex Function Dialysis Age Patient 
LD atTx Survival Donor Tx Dates CR BUN 
11-24-62 Mother 121M 
5-21-68 Father Since 1982 12 Alive Mother 11·24-62 Dialysis 
Father 5-21-68 Since 9-2-82 
2 1-31-63 Sister 381M Good 
13 15 Alive Mother 7-03-63 Failed 
3 2-9-63 Brother 211M Good Brother 7-27-87 Normal 
13 7-3-63 Mother 151M 17 15 Alive Mother 7-19-63 Normal 
7-27-87 Brother Good 
19 17 109d Mother' 7-26-63 
17 7-19-63 Mother 15/F Good Unrel M 8-09-63 
33 10-07-63 Mother 18/F Good 20 6 201d Mother' 7-29-63 
34 10-11-63 Mother 8/F 22 15 l1y 169d Mother 8-12-63 
9-14-82 Brother Good 
26 16 ld Father 8-29-63 
39 11-13-63 Mother 171M Good 
33 18 Alive Mother 10-07-63 Normal 
42 11-27-63 Father 19/F Good 
34 8 Alive Mother 10-11-63 Failed 
49 1-15-64 Sister 321M Good Brother 9-14-82 Normal 
50 1-25-64 Father 16/F 39 17 Alive Mother 11-13-63 Normal 
11-07-69 Mother 
41 3 14y 16d Mother 11-23-63 10-30-85 Cadaver Since 1987 
Cadaver M 1-22-70 
Cadaver F 6-29-70 51 2-10-64 Aunt 181M Good Cadaver F 2-27-71 
52 2-17-64 Father 15/F Good Cadaver F 12-29-72 
50 16 Alive Father 1-25-64 Dialysis 53 2-22-64 Uncle 151M Good 
Mother 11-07-69 Since 1987 
Cadaver 10-30-85 
Recipients ofGrafis From an Aunt, Uncle, and Cousin. 51 18 Alive Aunt 2-10-64 Normal 
One graft from an aunt and one from an uncle are still 52 15 Alive Father 2-17-64 Normal 
functioning well (Tables 1 and 2). A kidney from a second 
cousin was chronically rejected after 15 years and the 53 15 Alive Uncle 2-22-64 Normal 
recipient died not long after. 
Pediatric Vs Adult Recipients of Related Grafts. Of 16 61 5 36d Mother 3-23-64 
patients who were 18 years-old or younger at the time of Tx = transplantation; ReTx = retransplantation . 
transplantation, 10 (63%) are still alive, 8 are dialysis free, • A to 0 transplants. 
and 6 have good function of their original grafts (Table 3). 
In contrast, only 4 (13%) of 30 adults are alive, all with Because of the disproportionately high 25-year survival 
function of their original grafts of which 3 were from observed in infants and pediatric recipients, all 16 cases 
siblings, and the other from a parental donor. were examined retrospectively (Table 4). Four of the 6 
deaths occurred early from 1 to 201 days after transplan-
tation. Only 2 more deaths occurred in the next 25 years. 
Table 3. Pediatric Versus Adult Recipients in 46 
Related Transplantations Eighteen Colorado Recipients of Nonrelated 
Original Dialysis Volunteer Kidneys 
Number Alive Graft Free 
6(38%) 8(50%) None of these patients are alive (Table 1). The longest Pediatric (3-18 years) 16 10 (63%) kidney survival was 16;13 years (LD63) and the longest Adult (19-55 years) 30 4 (13%) 4 (13%) 4 (13%) 
patient survival (LD54) was 24.8 years (Table 5). 
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Table 5. Causes of 12 Deaths That Occurred After 10 Years 
Date of 
LD' Donor Date of Tx Age Death 
6 Brother 4-17-63 23 9-24-87 
12 Brother 6-07-63 48 7-15-80 
14 Brother 7-05-63 42 4-06-82 
22 Mother 8-12-63 15 1-28-75 
25 Brother 8-21-63 33 5-09-81 
37 Mother 10-18-63 21 2-10-89 





54 Unrelated 2-24-64 21 11-25-88 
Cadaver 9-26-66 
Cadaver 11-17-74 
55 Father 2-26-64 21 9-02-84 
58 Sister 3-13-64 27 10-10-74 
60 2nd Cousin 3-17-64 21 5-29-79 
Causes of Late Death in the Colorado Series 
At the end of 10 years, 24 (52.2%) of the 46 patients given 
living related kidneys, and 2 (11.1%) of 18 recipients of 
nonrelated kidneys were still alive. Twelve of these 26 
survivors died subsequently for reasons summarized in 
Table 5. Heart disease from coronary arteriosclerosis and 
cancer (4 examples each), were the principal reasons for 
the late deaths. Two patients stopped immunosuppression 
in what may have been covert suicides. They rejected their 
kidneys, and died of inadequately treated renal failure, 
Another patient with perfect renal function 17.7 years 
posttransplantation committed suicide with carbon mon-
oxide inhalation. One patient developed chronic active 
hepatitis and died of liver failure 10.6 years posttransplan-
tation. 
It was particularly distressing to have 3 patients die a 
few months before or just after the twenty-fifth anniver-
sary of their transplantation. Two of these patients (LD6 
and LD37) still had life supporting although subnormal 
renal function. One (LD6) was under consideration for 
heart transplantation and kidney retransplantation. 
Survivors From Other Centers Before 31 March 1964 
Nine additional survivors from this early era of renal 
transplantation are being followed in 6 centers (Table 6), 4 
Last Kidney 
Function 
Survival CR BUN Cause of Death 
24.4 5.0 73 Coronary artery disease 
17.1 1.7 16 Cancer of prostate 
18 1.2 19 Coronary artery disease 
11.6 Renal failure, stopped medications 
17.7 1.6 18 Suicide 
25.3 2.0 40 Coronary artery disease 
14 Renal failure 
24.8 1.2 20 Coronary artery disease 
20.5 1.5 25 Cancer of lung 
10.6 1.2 13 Liver failure from chronic active hepatitis 
15.2 Renal failure, multiple skin cancers 
in the United States and 2 in Europe. All 9 were recipients 
of kidneys from blood relatives. In 7 of the 9 cases, the 
original grafts are still functioning. In the other 2, retrans-
plantation many years later has made or kept the patients 
dialysis free; these patients who were treated in Paris 
(1962) and Edinburgh (1962) are the longest survivors in 
the world. 
DISCUSSION 
There are no patients left from the era preceding 1962 in 
which immunosuppression was with total body irradiation. 
However, the long survi val of two fraternal twin recipients 
from this earlier time provided an exceptional incentive for 
continuing efforts during an otherwise bleak period. The 
first of these twins whose operation was in Boston on 24 
January 1959,11.12.17 died in August 1979 of arteriosclerotic 
heart disease (personal communication, Dr Robert Kirk-
man, August 1989). The second fraternal twin underwent 
transplantation in Paris on 29 June 1959,18 and died on 13 
July 1985 of carcinoma of the bladder (personal communi-
cation, Dr Henri Kreis, August 1989). 
The subsequent wave of successes that began in 1962 
was made possible by the availability of azathioprine and 
by its combination with prednisone. March of 1964 was a 
natural demarcation point defining the end of this remark-
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With 1 st With 
Number Date Tx Where Done" Donor Age/Sex Physician Reports Follow-up by 
On 
Dialysis Graft RTx 
2·12-62 Paris Cousin 18 M J. Hamburger H. Kreis No Yes 
3-28-77 Sister 
2 7-27-62 Edinburgh Father 12 M M. Woodruff 22 M. Woodruff 1-83 to 1-86 No Yes 
1-86 Cadaver 
3 3-18-63 Richmond Brother 22 F D.Hume 25 G. Mendez-Picon, Yes 
H.M. Lee 
4 5-06-63 Boston Father 30M J. Murray, 20,21 R. Kirkman Yes 
J. Merrill 
5 5-16-63 Richmond Mother 14 F D.Hume 25 G. Mendez-Picon. Yes 
H.M. Lee 
6 7-16-63 Cleveland Brother 41 M W. Kolff 26 W. Braun Yes 
7 8-14-63 Minneapolis Mother 12 M W.O. Kelly, 27 J. Najarian Yes 
R. Lillehei 
8 12-27-63 Minneapolis Aunt 7F W.O. Kelly, 27 J. Najarian Yes 
R. Lillehei 
9 2-03-64 Richmond Sister 35 F O.Hume 25 G. Mendez-Picon, Yes 
H.M. Lee 
-Paris-Hopital Necker; Edinburgh-Western General Hospital; Boston-Peter Bent Brigham; Richmond-Medical College of Virginia; Cleveland-Cleveland Clinic; 
Minneapolis-University of Minnesota. 
able new phase. The cases compiled to that time at the 
University of Colorado provided the basis for the first 
textbook on renal transplantation. 16 In addition, this same 
time frame was used for a collection of all 342 renal 
homotransplantations done in the world up to March 
1964. 19 This latter extraordinary labor of love had been 
undertaken by the great transplantation pioneer, Dr Joseph 
E. Murray of Boston, following a meeting on 26 and 27 
September 1963 in Washington DC of about 20 early 
workers (surgeons, physicians, and pathologists) in this 
embryonal new specialty. The meeting was sponsored by 
the National Research Council and the National Academy 
of Science. 
Almost all of the survivors in the world at the time of the 
September 1963 meeting and up through the following 
March were treated at the same centers in Boston, Cleve-
land, Denver, Edinburgh, Minneapolis, Paris, and Rich-
mond where more than 25 years later the residual group of 
patients can be found today. Late reports from most of 
these centers have been published2G-27 but not for a 
number of years. The presence of these survivors contin-
ues to justify an effort which once was perceived by many 
as the height of folly. 28 
Ever since 1964. there was a growing uneasiness in the 
University of Colorado team about our dependence on 
living related donors; this is a concern which continues to 
haunt us to the present day. In addition, the failure to do 
better at the end of our 24-month trial than at the beginning 
of it had already convinced us that fundamental improve-
ments in tissue matching, in immunosuppression, or both 
would be necessary before renal transplantation would be 
truly practical. Consequently, a moratorium on renal 
transplantation was declared at the University of Colorado 
from March 1964 until the following October. When efforts 
were resumed, they included the first trial (with Dr Paul 
Terasaki at the University of California, Los Angeles) of 
prospective tissue matching.29 
By 1964 it became evident that the quality of life 
provided by nonrelated kidneys was inferior to that pro-
vided under the same conditions by living-related donor 
transplants. Furthermore, progress in the results of ca-
daver donor renal allografts appeared to be a clear prereq-
uisite to extension of clinical transplantation to nonrenal 
organs, which uniformly require cadaveric donors. It is 
worthy of note that none of the world's currently surviving 
23 long-term recipients was given an unrelated donor 
kidney. The longest continuous function of an unrelated 
kidney allograft in the University of Colorado series was 
16.7 years. There is no report, as yet, in the world of a 
25-year survival of a cadaveric kidney allograft, although a 
recipient in Paris who has maintained perfect renal func-
tion is expected to breach this barrier on 12 October 1989 
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(personal communication, Dr Henri Kreis, August 1989). 
This female recipient was 31 years-old at the time of her 
transplantation in 1964. 
A disquieting note in this series of patients is the 
continuing late mortality, which appears to bear no rela-
tionship to the organ source. In the University of Colorado 
series. 12 of the 26 patients alive at 10 years24 died 
subsequently. The higher rate of cancer seems to be 
related to chronic immunosuppression as was predicted 
from the beginning of this experience. 30 Cardiovascular 
disease seen in these patients may also have been a 
consequence of chronic immunosuppression. and particu-
larly of the use of steroids. It is of interest in this regard 
that the two patients who stopped their own immunosup-
pression more than 20 years ago remain free of these 
complications. These recipients have behaved almost as 
identical twin recipients studied during this era. Less than 
complete satisfaction with the outcome of transplantation 
may be inferred from the suicide of one patient and the 
occult suicide of2 other subjects. who refused to return to 
chronic dialysis after their kidney grafts had failed. 
At the time, the results observed during this era ending 
in March 1964 were considered revolutionary. A new field 
was deemed to have been opened with staggering scientific 
and social ramifications. The follow-up provided in this 
report is less of a justification of the technology then 
available than a sobering description of its limitations. The 
treatment options available today continue to have many 
of the same risk factors for truly long survival as the 
methods of 25 years ago. The results provide a stark 
warning against complacency regarding what we have to 
offer to transplant recipients today. 
SUMMARY 
A follow-up is provided for 64 patients treated with renal 
transplantation at the University of Colorado before 31 
March 1964. The 25-year survival was 15/64 (23.4%) and 14 
patients (22%) are still alive after 251/2 to 27 years. There 
are 9 other survivors in the world from this era, distributed 
in 4 American and 2 European centers. All of the 25-year 
survivors received their grafts from living related donors. 
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